Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Payables (2018 - 2026)

Exagen filings provide 9 years of Payables readings, the most recent being $4.2 million for Q1 2026.

  • On a quarterly basis, Payables fell 7.76% to $4.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $4.2 million, a 7.76% decrease, with the full-year FY2025 number at $4.2 million, changed 0.39% from a year prior.
  • Payables hit $4.2 million in Q1 2026 for Exagen, roughly flat from $4.2 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $4.5 million in Q1 2025 to a low of $1.1 million in Q3 2024.
  • Median Payables over the past 5 years was $3.1 million (2022), compared with a mean of $2.9 million.
  • Biggest five-year swings in Payables: plummeted 57.84% in 2023 and later soared 222.08% in 2025.
  • Exagen's Payables stood at $3.0 million in 2022, then grew by 2.79% to $3.1 million in 2023, then surged by 32.13% to $4.1 million in 2024, then increased by 0.39% to $4.2 million in 2025, then grew by 0.14% to $4.2 million in 2026.
  • The last three reported values for Payables were $4.2 million (Q1 2026), $4.2 million (Q4 2025), and $3.6 million (Q3 2025) per Business Quant data.